Skip to content

TA (1998) Psoriasis vulgaris treated successfully with mycophenolate mofetil

1998 Jan;138(1):179-81. Psoriasis vulgaris treated successfully with mycophenolate mofetil. Haufs MG(1), Beissert S, Grabbe S, Schtte B, Luger TA. Introduced in the 1970s as a treatment for psoriasis, mycophenolic acid has since been reformulated as mycophenolate mofetil (MMF). Clin Pharmacokinet 34(6):429-55 (1998 Jun). Psoriasis vulgaris treated successfully with mycophenolate mofetil. Haufs MGBeissert SGrabbe SSchtte BLuger TA Psoriasis vulgaris treated successfully with mycophenolate mofetil.

TA (1998) Psoriasis vulgaris treated successfully with mycophenolate mofetil 2The dosages of MMF ranged from 500 mg twice daily (for psoriasis and Crohn’s disease) to 1250 mg twice daily (for 3 of 4 patients with pemphigus vulgaris). Psoriasis vulgaris treated successfully with mycophenolate mofetil. 7Picknacker, A, Luger, TA, and Schwarz, T. Dyshidrotic eczema treated with mycophenolate mofetil. Psoriasis vulgaris treated successfully with mycophenolate mofetil. Pickenzacker A, Luger TA, Schwarz T. Dyshidrotic eczema treated with mycophenolate mofetil. Mycophenolate mofetil (MMF) is a novel immunosuppressant in the armamentarium of dermatologists, which is used for the treatment of immune-mediated skin disease. Mehling A, Grabbe S, Voskort M, Schwarz T, Luger TA, Beissert S. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. Psoriasis vulgaris treated successfully with mycophenolate mofetil. J Am Acad Dermatol 1998;39:497.

Mycophenolate mofetil (MMF) has been widely used as an immunosuppressant in organ transplantation. TA, Schwarz T. Dyshidrotic eczema treated with mycophenolate mofetil. Arch Dermatol 1998;134:378-9. Haufs MG, Beissert S, Grabbe S, Schtte B, Luger TA. 1998. Psoriasis vulgaris treated successfully with mycophenolate mofetil. 1998. Differentiation of cultured human epidermal keratinocytes at high cell densities is mediated by endogenous activation of the protein kinase C signaling pathway. An ester prodrug of MPA, mycophenolate mofetil (CellCept), has been developed and approved for the prevention of acute rejection in kidney, heart, or liver transplantation (for review, see Mele and Halloran, 2000) when used in combination with steroids and cyclosporine A (CsA). Haufs MG,; Beissert S,; Grabbe S,; Schutte B,; Luger TA. (1998) Psoriasis vulgaris treated successfully with mycophenolate mofetil.

Mycophenolate Mofetil In Autoimmune And Inflammatory Skin Disorders

Mycophenolate Mofetil In Autoimmune And Inflammatory Skin Disorders